Eirion Therapeutics Announces Initiation of First-in-Human Clinical Trial Evaluating Topical ET-02 for the Treatment of Androgenic Alopecia

Eirion Therapeutics, Inc. announced that the first participant has been enrolled in a Phase I clinical trial to evaluate the safety of the patented topical pharmaceutical ET-02 for the treatment of androgenic alopecia. This double-blind, placebo-controlled study is designed to determine the safety of ET-02 for once daily treatment over 28 days.